Investigational Therapy to Reprogram Patient’s Immune Response to Cancer Cells

This study is currently closed to enrollment.

AGE: 18 years and older
GENDER: All

TYPE: Drug Study (Cellular Therapy)
HEALTHY PARTICIPANTS: No

CONDITION: Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic

Study Purpose

University Hospitals-Seidman Cancer Center is now a participating site for a research study of an investigational therapy for patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small lymphocytic Lymphoma (SLL) disease. The overall purpose of this study is to evaluate the safety of JCAR017, determine the best dose for treating adults with relapsed and/or refractory CLL/SLL and evaluate the effectiveness of the dose selected adult participants.

CLL or SLL are a common kind of blood cancer that occurs when the bone marrow makes too many lymphocytes, or white blood cells. In CLL cancer cells are found mostly in the blood and bone marrow. In SLL cancer cells are found mostly in the lymph nodes. This study is an investigational therapy study where JCAR017 is made from the patients’ own blood cells and are used to reprogram the patient’s own immune system to recognize and attack the CLL and SLL cancer cells.